Trial Profile

Imaging of Solid Tumors Using FAP-2286

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium-68 FAP 2286-Clovis Oncology (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colon cancer; Head and neck cancer; Male breast cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
Focus Adverse reactions; Diagnostic use; First in man

Most Recent Events

21 Nov 2024 Planned number of patients changed from 116 to 131.
17 Sep 2024 Planned End Date changed from 30 Jun 2024 to 31 Dec 2025.
17 Sep 2024 Planned primary completion date changed from 30 Jun 2024 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com